FOX1 Promotes Tumor Progression by Upregulating CXCL8 in Colorectal Cancer

Junfeng Qiu1,2,3†, Mingzhou Li1,2,3†, Cailin Su1,2,3†, Yihao Liang4, Ruizhang Ou1,2,3, Xiaoning Chen1,2,3, Chengmei Huang1,2,3, Yaxin Zhang5, Yaping Ye1,2,3*, Wenting Liao1,2,3,5* and Chao Zhang5*

1 Department of Pathology, Nanfang Hospital, Southern Medical University, Guangzhou, China, 2 Department of Pathology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China, 3 Department of Pathology, Guangdong Provincial Key Laboratory of Molecular Tumor Pathology, Guangzhou, China, 4 The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, China, 5 State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China

Background: Forkhead box S1 (FOX1) is a member of the forkhead box (FOX) transcriptional factor superfamily. The biological roles and underlying regulatory mechanism of FOX1 in CRC remain unclear.

Methods: Bioinformatics analysis, Western blotting, real-time PCR, and immunohistochemistry (IHC) were used to detect the expression FOX1 in CRC. MTT assay, transwell assay, human umbilical vein endothelial cell tube formation assay, and chicken chorioallantoic membrane assay were performed to investigate the effects of FOX1 on proliferation, invasion, and angiogenesis. Additionally, tumor formation assay and orthotopic implantation assay were used to investigate the effects of FOX1 on tumor growth and metastasis in vivo. Furthermore, gene set enrichment analysis (GSEA) was used to analyze the correlation between FOX1 and EMT or angiogenesis. The correlation between FOX1 and CXCL8 expression was analyzed in clinical CRC samples using IHC.

Results: The results showed that FOX1 expression was upregulated in CRC tissues compared with adjacent normal intestine tissues. A high FOX1 expression is positively correlated with poor survival. FOX1 promoted the malignant behavior of CRC cancer cells in vitro, including proliferation, invasion, and angiogenesis. In addition, FOX1 promoted tumor growth and metastasis in nude mice. Mechanistically, FOX1 upregulated the expression of C-X-C motif chemokine ligand 8 (CXCL8) at the transcriptional level. Knockdown of CXCL8 blocked FOX1 induced the enhancement of the EMT and angiogenesis. GSEAs in public CRC datasets revealed strong correlations between FOX1 expression and EMT marker and angiogenesis markers. IHC showed that FOX1 expression was positively correlated with CXCL8 expression and CD31 expression in clinical CRC samples.
INTRODUCTION

Colorectal cancer (CRC) is the third most prevalent cancer in the world (1). About 20% of CRC patients have metastatic diseases in distant organs at the time of initial diagnosis (2). Despite of the improvement in combinational chemotheraphy and targeted therapies, the prognosis of metastatic CRC remains poor. The 5-year survival rate of CRC patients with liver metastasis is only about 14% (3). Angiogenesis plays a critical role in tumor growth and metastatic spread in CRC. Targeting angiogenesis through the vascular endothelial growth factor (VEGF) pathway has become an essential part of current therapies against metastatic CRC (4). A total of four anti-angiogenic drugs, namely, bevacizumab, aflibercept, ramucirumab, and regorafenib, have been approved by the US Food and Drug Administration for the treatment of metastatic CRC (5). However, the obtained survival benefit from anti-angiogenic drugs is limited due to a lack of validated predictive biomarkers and complicated resistance mechanisms (4). Therefore, development of valuable biomarkers and effective combinational therapeutic targets are urgently needed to impede the limitations of anti-angiogenic treatment for metastatic CRC patients.

Forkhead box S1 (FOXs1) is a member of the forkhead box (FOX) transcriptional factor superfamily. The FOX superfamily consists of 19 subclasses of Fox genes (FoxA to FoxS) (6). There are more than 50 FOX genes in the human genome. Each FOX gene contains a highly conserved forkhead (FKH) DNA-binding domain (7). Despite the similarity in their FKH DNA-binding domains, FOX proteins have divergent features and functions (8). For instance, the FOXP subfamily member FOXP3 is constitutively expressed in natural CD4+CD25+ T cells and has been shown to play critical roles during the differentiation and function of Treg cells (9). Unlike FOXP3, the FOXO subfamily members are mainly involved in the regulation of the cell cycle and are pivotal for the maintenance of tissue homeostasis in organs (10). Dysregulated FOX transcription factors are often found to be involved in developmental disorders and diseases such as cancer (11, 12). For example, FOXC1 and FOXC2 play critical roles in the development and metastasis of CRC (13, 14). FOXM1 is highly expressed in several cancers and has also been implicated in promoting angiogenesis, invasion, stemness, and drug resistance (15). Among FOX genes, FOXS1 is most closely homologous to FOXC1, FOXC2, and FOXL1 (8, 16). FOXS1 is predominantly expressed in the aorta and kidney (16). It is an early sensory neuronal marker (17). Early studies demonstrated that FOXS1 played critical roles in normal brain and testis development. FOXS1 deficiency leads to impaired sensory nerve cell development during embryonic development in mice and also results in a significant leakage of testicular blood vessels in mice (17–19). However, the expression pattern and biological function of FOXS1 in cancer are largely unknown.

In the current study, we reported that FOXS1 is upregulated in CRC. The overexpression of FOXS1 promotes tumor angiogenesis, invasion, and metastasis by upregulating C–X–C motif chemokine ligand 8 (CXCL8). These results uncover a novel role and underlying mechanism of FOXS1 in the progression of CRC, suggesting that the FOXS1/CXCL8 axis may be a promising anti-angiogenesis and tumor invasion target for the treatment of metastatic CRC.

MATERIALS AND METHODS

Patients and Specimens

Eleven pairs of fresh biopsies (including CRC tumor tissues and their matched non-cancerous mucosa tissues) were obtained from the operation room of Nanfang Hospital, Southern Medical University. The fresh biopsies were stored in liquid nitrogen before usage. The tissue microarray containing 39 cases of CRC tissues were collected from Nanfang Hospital, Southern Medical University. The use of clinical materials for research purposes was approved by the Southern Medical University Institutional Board (Guangzhou, China), and informed consent of the patients was obtained before collection, following relevant regulations. All the specimens were pathologically diagnosed as colon cancer by the pathology department, and all the specimens of the patients had not received radiotherapy and chemotherapy.

Cell Cultures

The human CRC cell lines HCT116, SW480, SW620, HT29, CaCo2, Colo205, DLD1, LS174T, HCT15, HCT8, RKO, SW837, and LoVo were purchased from the American Type Culture Collection and were stored in the Department of Pathology, Southern Medical University, China. SW620, SW480, and SW837 cells were cultured in Leibovitz’s L-15 medium (Gibco, Grand Island, NY, USA) supplemented with 10% fetal bovine serum (FBS) (Gibco). HCT116 cells were cultured in McCoy’s 5A medium (Gibco) with 10% FBS. LoVo, Caco2, and HT29 cells were cultured in DMEM medium (Gibco) supplemented with 10% FBS. HCT15, DLD1, LS174T, HCT8, RKO, and Colo205 cells were cultured in RPMI 1640 medium (Gibco) with 10% FBS. Human umbilical vein endothelial cells (HUVECs) were cultured in DMEM containing F12K medium (Gibco) and 20% FBS (Gibco). All cells were cultured at 37°C in a 5% CO2 atmosphere.

Plasmids

The FOXS1 construct was generated by cloning PCR-amplified full-length human FOXS1 cDNA into pLenti-EF1a. To delete
FOXS1, two short hairpin RNA (shRNA) sequences (FOXS1 shRNA#1: CCGGTAGTGGCATCTACGGCTACACT CGAGAGTGCACTACCGCTACATTTTG; FOXS1 shRNA#2: CCGGTCTACCTAAGAGTGGCTTTGTGCTCGA GCACCTAACCAGTGCTTTGTGTTTTT) were cloned into pLKO.1. Vectors pLenti-EF1a and pLKO.1 were purchased from Addgene Inc. (Watertown, MA, USA).

**RNA Isolation, Reverse Transcription, and Real-Time PCR**
RNA was isolated by RNeasy Plus (Takara, 9109). Real-time quantitative reverse transcription PCR (real-time qPCR) was performed in triplicate using SYBR Green Mix (Vazyme, Nanjing, China, Q711-02) and the ABI PRISM 7500 Sequence Detection System (Applied Biosystems, Foster City, CA, USA). The multiple-ratio relationship of the target gene expression between the experimental group and control group was calculated using the $2^{-\Delta\Delta Ct}$ method. The housekeeping gene GAPDH was used as an internal control. Primer Express was used to design the real-time PCR primers, and primer sequences for amplification are shown in Supplementary Table S1.

**Western Blotting Analysis**
Western blotting analysis was performed as previously described (20), using the FOXS1 (Sigma, St. Louis, MO, USA, HPA042475), anti-CXCL8 (Bioss, Woburn, MA, USA, bs-0780R), and anti-Flag (Bioss, bs-10583R) antibodies. Mouse monoclonal anti-β-tubulin antibody (Sigma, #9026) was used as the internal control.

**Immunohistochemistry**
Immunohistochemistry (IHC) staining and scoring were performed as previously described (21) using anti-FOX5 (Sigma, HPA042475), anti-CD31 (Abcam, Cambridge, MA, USA, ab9498), and anti-CXCL8 (Bioss, bs-0780R) antibodies. The degree of IHC staining was reviewed and scored independently by two observers. The intensity of staining was graded according to the following criteria: 0 (no staining), 1 (weak staining = light yellow), 2 (moderate staining = yellow brown), and 3 (strong staining = brown). The intensity of staining ≥2 was used to define tumors as high expression and ≤1 as low expression.

**Methyl Thiazolyl Tetrazolium Assay**
Cells (1 × 10^5) were seeded on 96-well plates and cultured for 24 h. Twenty microliters of 5 mg/ml methyl thiazolyl tetrazolium (MTT) (Sigma, St. Louis, MO, USA) was added to each well and incubated for 4 h. The reaction liquid was then removed, and 100 μl dimethyl sulfoxide (DMSO, Sigma, St. Louis, MO, USA) was added to the wells. The absorbance was measured at 570 nm with a Microplate Autoreader (Bio-Rad, Hercules, CA, USA). The experiment was repeated three times.

**Colony-Formation Assay**
Tumor cells were seeded on a six-well plate (200 cells/well) and incubated at 37°C in a humidified 5% CO₂ atmosphere incubator for 2 weeks. Cells were fixed and stained with crystal violet (KeyGEN BioTECH). Colonies containing 450 cells were counted. Three independent experiments were performed for each cell line.

**Migration Assay and Invasion Assay**
Eight-micrometer-pore filter membranes of the Boyden chambers were used for the migration assay. Tumor cells (1 × 10^5) in culture medium containing 1% FBS were seeded in the upper chamber, and culture medium with 10% FBS was added in the lower chamber as a chemoattractant. For invasion assay, the upper side of the filter was coated with 0.2% Matrigel (BD Biosciences, San Jose, CA, USA). After incubation for 24 h, cells on the upper side of the filter were removed with cotton swabs. Cells that migrated to the lower surface of the filter were fixed in 4% paraformaldehyde and stained with crystal violet (KeyGEN BioTECH). Three independent experiments were performed.

**Chicken Chorioallantoic Membrane Assay**
The chicken chorioallantoic membrane (CAM) assay was performed on the sixth day of development of fertilized chicken eggs as previously described (22).

**Human Umbilical Vein Endothelial Cell Tube Formation Assay**
Precooled 24-well plate plates were coated with Matrigel Basement Membrane Matrix (BD Biosciences, Franklin Lakes, NJ, USA) and then allowed to polymerize at 37°C for 30 min. HUVECs (1 × 10^5) in 200 ml of conditioned medium were added to each well and incubated at 37°C in 5% CO₂ for 8 h. Images were obtained under a bright-field microscope, and the capillary tubes were quantified by counting the length. Three independent experiments were performed.

**Subcutaneous Tumor Formation and Orthotopic Mouse Metastatic Model**
The female BALB/c nude mice (4 to 6 weeks old) were obtained from the Animal Center of Southern Medical University, Guangzhou, China. All mice with animal feeding certificates were raised in an SPF-level environment. All animal experiments were conducted in accordance with standard procedures and approved by the Institutional Use Committee for Animal Care. For subcutaneous tumor formation, 1 × 10^6 cells were subcutaneously injected into the right dorsal flank of female BALB/c athymic nude mice (4–6 weeks of age, 18–20 g). Tumor volume (V) was monitored every 2 days by measuring the short axis (W) and long axis (L) of the xenograft tumor and calculated with the following formula: $V = (L \times W^2)/2$. All mice were sacrificed 19 days after inoculation. The tumors were excised and fixed with 10% neutral formalin and paraffin embedded for histology analysis. The orthotopic metastatic model was established as previously described (23). Nude mice were anesthetized and 1 × 10^6 cells were injected into the cecal serosal layer. The mice were sacrificed when they reached endpoint criteria (moribund or lost 20% of their pre-
experiment body weight). The individual organs were excised, and metastases were observed by histological analysis. The numbers of gross metastatic foci were determined using a dissection microscope.

**Statistical Analysis**

SPSS 20.0 statistical software was used for data analysis. Two-tailed independent Student’s t-test was used to analyze two groups. The relationship between FOXS1 expression level and overall survival rate was calculated by the Kaplan–Meier method, and the difference in overall survival rate was statistically compared by the log-rank method. Spearman correlation analysis was used for expression correlation analysis. The relationship between pathological parameters was compared using the two-independent-sample non-parametric test and a chi-square test. One-way ANOVA test was used to compare the differences of data from multiple groups, and LSD-T was used for multiple comparisons. \( p < 0.05 \) was considered significant (* \( p < 0.05 \), ** \( p < 0.01 \), *** \( p < 0.001 \)).

**RESULTS**

**FOXS1 Is Upregulated in CRC and Associated With a Poor Prognosis**

The expression of FOXS1 expression was analyzed in TCGA COAD and READ databases, showing that FOXS1 was significantly upregulated in CRC tissues compared with that in normal colon and rectal tissues (Figure 1A). RT-PCR and IHC were used to detect the expression levels of FOXS1 in 11 CRC samples and their paired adjacent normal tissues. The results showed that the mRNA level of FOXS1 was significantly higher in CRC tissues than in the paired adjacent normal tissues (Figure 1B). IHC showed that positive FOXS1 expression was mainly localized in the nuclei and cytoplasm, as marked by yellow-brown staining (Figure 1C). Consistent with the mRNA expressions, IHC results showed that the protein level of FOXS1 was significantly higher in CRC tissues than in the paired adjacent normal tissues (Figure 1C). Kaplan–Meier survival analysis of TCGA-COAD datasets revealed a significantly poorer 5-year overall survival rate in patients with CRC with a high FOXS1 expression than in patients with a low FOXS1 expression (Figure 1D). These results suggested that FOXS1 is upregulated in CRC tissues.

**FOXS1 Promotes Proliferation and Invasiveness of CRC Cells**

A gene set enrichment analysis (GSEA) was used to examine the FOXS1-regulated gene signatures. According to the results of the GSEA, a higher FOXS1 expression was positively correlated with the enrichment of epithelial–mesenchymal transition and angiogenesis-related gene signatures (TCGA and GSE17536) (Figure 2A). To investigate the role of FOXS1 in CRC progression, stable overexpression cell lines were established in RKO and SW837 cell lines, which showed a low endogenous expression of FOXS1. In addition, endogenous FOXS1 was knocked down in CaCO2 and HCT15 CRC cells, which display a high endogenous expression of FOXS1. In addition, endogenous FOXS1 was knocked down in CaCO2 and HCT15 CRC cells, which display a high endogenous FOXS1 expression (Supplemental Figures S1A, B). MTT assay and clone formation assay showed that FOXS1 overexpression significantly increased the proliferation,

---

**FIGURE 1** | FOXS1 is upregulated in CRC and associated with a poor prognosis. (A) Analysis of FOXS1 expression in CRC compared with normal tissues in TCGA COAD and TCGA READ databases. FOXS1 expressions in paired CRC cancer tissues and adjacent normal tissues in TCGA COAD and TCGA READ datasets were also compared. (B) Real-time PCR analysis of FOXS1 expression in paired human CRC tissues and adjacent non-cancerous tissues. (C) The expression of FOXS1 in normal intestinal tissues and CRC tissues was examined by IHC. Representative IHC images (left) and correlation analysis (right) are shown. Scale bars: 50 µm. (D) Kaplan–Meier analysis of overall survival in all CRC patients in TCGA database according to FOXS1 expression (log-rank test, \( p = 0.014 \), * \( p < 0.05 \), *** \( p < 0.001 \).
while knockdown of FOXS1 significantly decreased the cell proliferation in vitro (Figures 2B–E). Migration and invasion assays showed that overexpression of FOXS1 obviously increased the migratory and invasive abilities in RKO and SW837 cell lines (Figure 2F and Supplemental Figure S2A). On the contrary, knockdown of FOXS1 obviously suppressed the migratory and invasive abilities in CaCO2 and HCT15 cell lines (Figure 2G and Supplemental Figure S2B). Subcutaneous inoculation assay showed that overexpression of FOXS1 significantly increased (Figure 3A), while knockdown of FOXS1 significantly decreased the tumor growth in nude mice (Figure 3B). Orthotopic inoculation assay showed that overexpression of FOXS1 increased the liver metastases (Figures 3C–E) and shortened the overall survival of the mice (Figure 3F).

**FOXs1 Is Involved in Tumor Cell-Induced Angiogenesis**

Since GSEAs revealed that a higher FOXS1 expression was positively correlated with the enrichment of the angiogenesis-related gene signature (Figure 2A), we performed tube formation, HUVEC migration assay, and chicken CAM assays to validate the effect of FOXS1 on tumor cell-induced angiogenesis. The results showed that overexpression of FOXS1 strongly promoted the formation of tubes by HUVECs (Figure 4A), promoted HUVEC migration toward the conditioned medium (Figure 4B), and increased angiogenesis in CAMs (Figure 4C). However, knockdown of FOXS1 significantly suppressed the formation of tubes by HUVECs (Figure 4D) and inhibited HUVEC migration toward the conditioned medium (Figure 4E). Moreover, FOXS1-overexpressing tumors had a higher microvascular density (indicated by CD31-positive cells) than control tumors (Supplemental Figure S3A). On the contrary, FOXS1-knockdown tumors had a decreased microvascular density (indicated by CD31-positive cells) as compared with control tumors (Supplemental Figure S3B). These results revealed that FOXS1 played an important role in tumor cell-induced angiogenesis in CRC.
FOXS1 Promotes EMT and Angiogenesis by Upregulating CXCL8

Secreted proteins play integral roles in the cross talk between tumor cells and the tumor microenvironment. To identify essential genes that may underlie FOXS1-mediated angiogenesis and CRC development and progression, we integrated data across (i) angiogenesis signatures (Supplementary Table S2), (ii) genes that are upregulated in tumors versus normal tissues (GSE18105, Supplementary Table S3), and (iii) secretory proteins set from the Protein Atlas (https://www.proteinatlas.org/). These multidimensional datasets triangulated on two genes, CXCL8 and VEGFA (Figure 5A, left). To analyze whether FOXS1 would regulate the expression of CXCL8 and VEGFA at the transcriptional level, the FOXS1 motif (orange boxes) was searched on the promoter loci of the CXCL8 gene and VEGFA gene in the JASPAR database. Several FOXS1 motif loci were found on the CXCL8 promoter. Only one FOXS1 motif locus was found on the VEGFA promoter (Figure 5A, right). Q-RT-PCR showed that overexpression of FOXS1 significantly upregulated CXCL8, while knockdown of FOXS1 dramatically suppressed CXCL8 expression (Figure 5B). However, overexpression or knockdown of FOXS1 has no effect on the expression of VEGFA (Supplemental Figure S4). Next, we detected whether CXCL8 was involved in FOXS1-mediated EMT and angiogenesis. Q-RT-PCR (Figure 5C) showed that knockdown of FOXS1 significantly upregulated the expression of epithelial markers (ZO1, E-cadherin, and a-catenin), while it suppressed the mesenchymal markers (N-cadherin and vimentin) and EMT inducers (Claudin-1, SNAI1, and ZEB1). In contrast, overexpression of FOXS1 significantly suppressed the expression of ZO1, E-cadherin, and a-catenin, while it upregulated N-cadherin, vimentin, Claudin-1, SNAI1, and ZEB1. Knockdown of CXCL8 significantly downregulated N-cadherin, vimentin, Claudin-1, SNAI1, and ZEB1, while it upregulated ZO1, E-cadherin, and a-Catenin in FOXS1-overexpressing cells (Figure 5C). To investigate whether FOXS1 promotes EMT and angiogenesis by upregulating CXCL8, FOXS1-overexpressing cells were transfected with CXCL8 siRNAs. It was shown that knockdown of CXCL8 significantly suppressed the FOXS1-driven migration and invasiveness in CRC cells (Figure 5D) and inhibited the FOXS1-mediated tube formation ability in vitro (Figure 5E). These results suggested that FOXS1 promoted EMT and angiogenesis by upregulating CXCL8.

FOXS1 Expression Positively Correlates With Angiogenesis and CXCL8 Expression in CRC

To assess a potential link between FOXS1 and angiogenesis expression in human CRC, correlation analyses were performed in GSE39582 and TCGA datasets. The results revealed a strong positive correlation between high expression levels of FOXS1 and
angiogenesis markers (CD31, CD34, CD105, and CD146) (Figure 6A). In addition, FOXS1 was positively correlated with EMT inducers (SNAI1, ZEB1, ZEB2) and mesenchymal marker vimentin, while it was negatively correlated with the epithelial marker CDH1 in both TCGA and GSE39582 datasets (Supplemental Figure S5). Moreover, FOXS1 expression is positively correlated with CXCL8 in both TCGA and GSE39582 datasets (Figure 6B). Furthermore, the analysis of a CRC tissue microarray including 39 CRC tissues revealed a significant positive correlation between FOXS1 expression and CXCL8 expression or microvascular density (indicated by CD31-positive cells) (Figure 6C).

**FIGURE 4** | FOXS1 is involved in tumor cell-induced angiogenesis. (A) HUVEC tube formation after stimulation with the indicated conditional medium from vector control CRC cells and FOXS1-overexpressed CRC cells. Scale bars: 50 µm. The number of tube junctions was calculated (right). (B) Migration of HUVECs toward conditioned medium from vector control CRC cells and FOXS1-overexpressed CRC cells. Scale bars: 50 µm. The number of migrated HUVECs was calculated. (C) Representative images of the CAM assay. Histograms show the formation of secondary and tertiary blood vessels after stimulation with the indicated conditional medium from FOXS1-overexpressing cells. (D) HUVEC tube formation after stimulation with the indicated conditional medium from FOXS1-depleted CRC cells. Scale bar: 50 µm. The number of tube junctions was calculated (right). (E) Migration of HUVECs toward conditioned medium from FOXS1-depleted CRC cells. The number of migrated HUVECs was calculated. Scale bar: 50 µm. *p < 0.05, **p < 0.01, ***p < 0.001.
DISCUSSION

FOXS1 is a member of the forkhead box family of transcription factors. The role of FOXS1 in the development and progression of human cancers is largely unknown. There are only a few studies that have reported that FOXS1 was involved in the regulation of cancer cell biology in gastric cancer (24, 25), hepatocellular carcinoma (26, 27), and glioma cells (28). Nevertheless, the role of FOXS1 in cancer remains controversial according to the results from these studies. For example, Lu reported that FOXS1 is downregulated in gastric cancer, and overexpression of FOXS1 inhibits proliferation, metastasis, and EMT in gastric cancer cell lines (25). On the contrary, Wang’s study in a large sample size of clinical tissues showed that FOXS1 is overexpressed in gastric cancer, and a high expression of FOXS1 significantly correlated with an aggressive phenotype and poor prognosis in patients with gastric cancer. In addition, they found that overexpression of FOXS1 promoted cell proliferation and EMT (24). Bévant et al. showed that FOXS1 could be epigenetically silenced in non-tumor tissues through DNA hypermethylation. A high expression of FOXS1 predicted a poor prognosis in liver cancer. In addition, overexpression of FOXS1 induced EMT markers and promoted cell migration and metastasis in liver cancer (26). On the contrary, Lei et al. reported that FOXS1 is downregulated in hepatocellular carcinoma and overexpression of FOXS1 inhibited the proliferation and migration of hepatocellular carcinoma cells (27). These studies demonstrated conflicting results, probably due to using different cell lines. In gastric cancer, FOXS1 overexpression inhibits EMT in SNU-216 cells (25) but promotes EMT in SGC7901 and BGC823 cells (24). In liver cancer, Bévant et al. showed that FOXS1 evidently promoted EMT in PLC/PRF/5 (26), while Lei et al. demonstrated that FOXS1 suppressed EMT in Huh7 and Hep3B cell lines (27). These opposite results suggest that the function of FOXS1 could be dependent on specific cell-cell-specific contexts associated with different genetic/epigenetic
backgrounds of cancer subtypes. In the present study, we found that FOXS1 was upregulated in TCGA CRC datasets and clinical CRC samples. FOXS1 expression was significantly correlated with a poorer prognosis for patients with CRC. Overexpression of FOXS1 promotes cancer cell proliferation, invasiveness, angiogenesis, tumor growth, and metastasis. FOXS1 protein shares a high degree of similarity with FOXC2, which induces EMT and promotes metastasis (29). Taken together, regardless of previously contradictory reports in gastric cancer and hepatocellular carcinoma, our results indicate that FOXS1 might be a candidate oncogene in CRC.

Metastasis is a complex, multigene-involved, multistage process. EMT and angiogenesis are important features of tumors during invasion and metastasis (30). Members of the forkhead transcription factors, e.g., FOXC1 and FOXC2, are involved in angiogenesis and metastasis through various pathways (29, 31–33). As the structure of FOXS1 is highly similar with FOXC2, we propose that they may share similarities in their biological functions in human cancers. Recently, it has been reported that FOXS1 promoted EMT and was related to temozolomide resistance in glioma cells (28). In addition, FOXS1 was regulated by GLI1 and miR-125a-5p. Overexpression of FOXS1 promoted cell proliferation and EMT in gastric cancer (24). Moreover, FOXS1 induced by TGFβ promoted a classical model of EMT by activating the expression of EMT-transcription factors (SNAI1, and SNAI2) in hepatocellular carcinoma (26). As compared with the role of FOXS1 in EMT, the function of FOXS1 tumor angiogenesis is rarely known. FOXS1 was expressed in blood vessel-associated smooth muscle cells and pericytes in the central nervous system (18). Deletion of FOXS1 led to deficiency in the development of the testicular vasculature (19). These studies implicated a potential role of FOXS1 in angiogenesis in tumor. In the present study, we provided evidence that FOXS1 not only promoted EMT in CRC cells but also was involved in angiogenesis in human cancers.

Angiogenesis is crucial for the growth and metastasis of aggressive tumors (34). VEGF, angiopoietins, Notch, and integrins are key signaling pathways that regulate and orchestrate angiogenesis (35). Anti-angiogenesis by targeting...
the VEGF pathway using monoclonal antibodies (mAbs), small molecules, and tyrosine kinase inhibitors (TKIs) is an important part of controlling cancer progression (36). However, the obtained survival benefits from the current anti-angiogenic drugs are limited due to multiple resistance mechanisms (37). CXC chemokines containing the ELR motif (ELR+) are well known by their ability to promote angiogenesis (38). CXCL8, an ELR+ CXC chemokine, also known as IL8, has a demonstrated angiogenic activity (39, 40). Like other ELR+ CXC chemokines, CXCL8 binds to and acts on CXCR1 and CXCR2, especially CXCR2 (41). The proangiogenic activity of CXCL8 occurs predominantly following the interaction with CXCR2 (42). CXCR2, as the putative receptor for ELR+ CXC chemokine-induced angiogenic activity, is widely expressed in tumor cells and stroma cells such as endothelial cells and leukocytes (42–44). It was reported that the CXCL8–CXCR2 axis induces VEGF transcription and stimulates the autocrine activation of VEGFR2 in endothelial cells (45). In addition to promoting angiogenesis, the CXCL8/CXCR2 axis also exerts multiple effects on proliferation, invasion, and migration of tumor cells (41). The CXCL8/CXCR2 axis plays important roles in the initiation and development of various cancers including CRC, breast cancer, prostate cancer, and lung cancer (46–49). CXCL8 is upregulated in various cancers and are correlated with tumor stages and patient prognosis (50). The expression of CXCL8 is inducible under hypoxic conditions in several types of tumor cells, mainly through the cooperative activation of interferon, NF-κB, and activator protein-1 (AP-1) (51–53). In this study, we demonstrated that CXCL8 was upregulated by a forkhead transcriptional factor, FOXS1. The FOXS1/CXCL8 axis promoted tumor cell migration, invasion, angiogenesis, and metastasis in CRC, suggesting that FOXS1/CXCL8 may be a novel target in disrupting tumor-associated angiogenesis and in controlling advanced CRC.

CONCLUSION

In conclusion, our data suggest that FOXS1 has an essential role in CRC angiogenesis and metastasis by regulating CXCL8. Interference with the FOXS1/CXCL8 axis may represent a new anti-angiogenic treatment option to prevent or reduce the metastasis of CRC.

REFERENCES

1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin (2021) 71(1):7–33. doi: 10.3322/caac.21654
2. Brenner H, Kloos M, Fox CP. Colorectal Cancer. Lancet (2014) 383 (9927):1490–502. doi: 10.1016/S0140-6736(13)61649-9
3. Siegel RL, Miller KD, Goding Sauer A, Fedewa SA, Butterly LF, Anderson JC, et al. Colorectal Cancer Statistics, 2020. CA Cancer J Clin (2020) 70(3):145–64. doi: 10.3322/caac.21601
4. Apte RS, Chen DS, Ferrara N. VEGF in Signaling and Disease: Beyond Discovery and Development. Cell (2019) 178(6):1248–64. doi: 10.1016/j.cell.2019.01.021
5. Mody K, Baldeo C, Bekaii-Saab T. Antiangiogenic Therapy in Colorectal Cancer. Cancer J (2018) 24(4):165–70. doi: 10.1097/PPO.0000000000000328
6. Jackson BC, Carpenter C, Nebert DW, Vasiliou V. Update of Human and Mouse Forkhead Box (FOX) Gene Families. Hum Genomics (2010) 4(5):345–52. doi: 10.1186/1479-7364-4-5-345
7. Hannenhalli S, Kaestner KH. The Evolution of Fox Genes and Their Role in Development and Disease. Nat Rev Genet (2009) 10(4):233–40. doi: 10.1038/nrg2523
8. Golson ML, Kaestner KH. Fox Transcription Factors: From Development to Disease. Development (2016) 143(24):4558–70. doi: 10.1242/dev.112672
9. Hori S, Nomura T, Sakaguchi S. Control of Regulatory T Cell Development by the Transcription Factor Foxp3. Science (2003) 299(5609):1057–61. doi: 10.1126/science.1079490
10. Calnan DR, Brunet A. The FoxO Code. Oncogene (2008) 27(16):2276–88. doi: 10.1038/onc.2008.21
11. Myatt SS, Lam EW. The Emerging Roles of Forkhead Box (Fox) Proteins in Cancer. Nat Rev Cancer (2007) 7(11):847–59. doi: 10.1038/nrc2223

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by The Institutional Committee of Southern Medical University and Nanfang Hospital. The patients/participants provided their written informed consent to participate in this study. The animal study was reviewed and approved by Committee on the Ethics of Animal Experiments of Southern Medical University. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

AUTHOR CONTRIBUTIONS

The first authors, JQ, ML, and CS, provided the study concept and designed this study. JQ and ML carried out the experiments and analyzed the data. ML wrote the first draft. The corresponding author WL was predominantly engaged in organizing, designing, and writing the article. Other authors contributed equally to the paper’s conception, literature review, writing, and editing of the figures. Each author approved the final version of the manuscript.

FUNDING

This work was supported by grants from the National Natural Science Foundation of China (No. 81872401, 81672886).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2022.894043/full#supplementary-material
12. Lassie P. The Forkhead-Box Family of Transcription Factors: Key Molecular Players in Colorectal Cancer Pathogenesis. *Mol Cancer* (2019) 18(1):5. doi: 10.1186/s12943-019-0938-x

13. Cui YM, Jiang D, Zhang SH, Wu P, Ye YP, Chen CM, et al. FOXC2 Promotes Colorectal Cancer Proliferation Through Inhibition of FOXO3a and Activation of MAPK and AKT Signaling Pathways. *Cancer Lett* (2014) 353(1):87–94. doi: 10.1016/j.canlet.2014.07.008

14. Liu J, Zhang Z, Li X, Chen J, Wang G, Tian Z, et al. Forkhead Box C1 Promotes Colorectal Cancer Metastasis Through Transactivating IGTA7 and FGFR4 Expression. *Oncogene* (2018) 37(41):5477–91. doi: 10.1038/s41388-018-0355-4

15. Kalathil D, John S, Nair AS. FOXM1 and Cancer: Faulty Cellular Signaling. *Frontiers in Oncology* | www.frontiersin.org July 2022 | Volume 12 | Article 894043

16. Cederberg A, Betz R, Lagercrantz S, Larsson C, Hulander M, Carlsson P, et al. Chromosome Localization, Sequence Analysis, and Expression Pattern Identify FKHL 18 as a Novel Human Forkhead Gene. *Genomics* (1997) 44(3):344–6. doi: 10.1006/geno.1997.4864

17. Montelius A, Marmigere F, Aquino JB, Enerback S, Ernfors P. FOXC2 Promotes Colorectal Cancer Progression Through Inhibition of FOXO3a and Activation of MAPK and AKT Signaling Pathways. *Cancer Lett* (2014) 353(1):87–94. doi: 10.1016/j.canlet.2014.07.008

18. Liu J, Zhang Z, Li X, Chen J, Wang G, Tian Z, et al. Forkhead Box C1 Promotes Colorectal Cancer Metastasis Through Transactivating IGTA7 and FGFR4 Expression. *Oncogene* (2018) 37(41):5477–91. doi: 10.1038/s41388-018-0355-4

19. Montelius A, Marmigere F, Aquino JB, Enerback S, Ernfors P. FOXC2 Promotes Colorectal Cancer Progression Through Inhibition of FOXO3a and Activation of MAPK and AKT Signaling Pathways. *Cancer Lett* (2014) 353(1):87–94. doi: 10.1016/j.canlet.2014.07.008

20. Liu J, Zhang Z, Li X, Chen J, Wang G, Tian Z, et al. FOXC2 Promotes Colorectal Cancer Progression Through Inhibition of FOXO3a and Activation of MAPK and AKT Signaling Pathways. *Cancer Lett* (2014) 353(1):87–94. doi: 10.1016/j.canlet.2014.07.008

21. Liu J, Zhang Z, Li X, Chen J, Wang G, Tian Z, et al. FOXC2 Promotes Colorectal Cancer Progression Through Inhibition of FOXO3a and Activation of MAPK and AKT Signaling Pathways. *Cancer Lett* (2014) 353(1):87–94. doi: 10.1016/j.canlet.2014.07.008

22. Liu J, Zhang Z, Li X, Chen J, Wang G, Tian Z, et al. FOXC2 Promotes Colorectal Cancer Progression Through Inhibition of FOXO3a and Activation of MAPK and AKT Signaling Pathways. *Cancer Lett* (2014) 353(1):87–94. doi: 10.1016/j.canlet.2014.07.008

23. Liu J, Zhang Z, Li X, Chen J, Wang G, Tian Z, et al. FOXC2 Promotes Colorectal Cancer Progression Through Inhibition of FOXO3a and Activation of MAPK and AKT Signaling Pathways. *Cancer Lett* (2014) 353(1):87–94. doi: 10.1016/j.canlet.2014.07.008

24. Liu J, Zhang Z, Li X, Chen J, Wang G, Tian Z, et al. FOXC2 Promotes Colorectal Cancer Progression Through Inhibition of FOXO3a and Activation of MAPK and AKT Signaling Pathways. *Cancer Lett* (2014) 353(1):87–94. doi: 10.1016/j.canlet.2014.07.008

25. Liu J, Zhang Z, Li X, Chen J, Wang G, Tian Z, et al. FOXC2 Promotes Colorectal Cancer Progression Through Inhibition of FOXO3a and Activation of MAPK and AKT Signaling Pathways. *Cancer Lett* (2014) 353(1):87–94. doi: 10.1016/j.canlet.2014.07.008

26. Liu J, Zhang Z, Li X, Chen J, Wang G, Tian Z, et al. FOXC2 Promotes Colorectal Cancer Progression Through Inhibition of FOXO3a and Activation of MAPK and AKT Signaling Pathways. *Cancer Lett* (2014) 353(1):87–94. doi: 10.1016/j.canlet.2014.07.008

27. Liu J, Zhang Z, Li X, Chen J, Wang G, Tian Z, et al. FOXC2 Promotes Colorectal Cancer Progression Through Inhibition of FOXO3a and Activation of MAPK and AKT Signaling Pathways. *Cancer Lett* (2014) 353(1):87–94. doi: 10.1016/j.canlet.2014.07.008

28. Liu J, Zhang Z, Li X, Chen J, Wang G, Tian Z, et al. FOXC2 Promotes Colorectal Cancer Progression Through Inhibition of FOXO3a and Activation of MAPK and AKT Signaling Pathways. *Cancer Lett* (2014) 353(1):87–94. doi: 10.1016/j.canlet.2014.07.008

29. Liu J, Zhang Z, Li X, Chen J, Wang G, Tian Z, et al. FOXC2 Promotes Colorectal Cancer Progression Through Inhibition of FOXO3a and Activation of MAPK and AKT Signaling Pathways. *Cancer Lett* (2014) 353(1):87–94. doi: 10.1016/j.canlet.2014.07.008

30. Liu J, Zhang Z, Li X, Chen J, Wang G, Tian Z, et al. FOXC2 Promotes Colorectal Cancer Progression Through Inhibition of FOXO3a and Activation of MAPK and AKT Signaling Pathways. *Cancer Lett* (2014) 353(1):87–94. doi: 10.1016/j.canlet.2014.07.008
Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Qiu, Li, Su, Liang, Ou, Chen, Huang, Zhang, Ye, Liu and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.